DIANA Biotechnologies

Executive Summary

DIANA Biotechnologies is a Czech biotech company founded in 2018, originating from the Institute of Organic Chemistry and Biochemistry (IOCB) in Prague. The company provides innovative PCR and RT-PCR products, custom oligonucleotide synthesis, monoclonal antibody development, and kinase inhibitor profiling services to diagnostic and life science laboratories globally. Operating as an OEM provider and service partner, DIANA supports diagnostics, life science research, and drug discovery sectors. Its academic roots and expertise in nucleic acid chemistry and kinase biology give it a competitive edge in molecular biology tools and custom biologics. As a privately held firm without disclosed funding or valuation, DIANA's growth depends on expanding its customer base and developing proprietary technologies. The global diagnostics and life science market offers significant opportunities, but the company's small size and limited commercial pipeline pose challenges. Focused on high-quality reagents and custom services, DIANA is well-positioned to capture demand in PCR-based solutions and drug discovery support, though near-term financial visibility is limited.

Upcoming Catalysts (preview)

• Q3 2026Launch of novel RT-PCR kit for infectious disease detection70% success
• Q4 2026Strategic partnership with major diagnostics company50% success
• Q1 2027Expansion of custom antibody service into US market40% success